Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4396 AL 4410

Old and new acetylcholinesterase inhibitors for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Investig Drugs. 2016 Oct;25(10):1181-7. doi: 10.1080/13543784.2016.1216972. Epub 2016 Aug 5.

[Progress of clinical trials in Alzheimer’s disease drugs]

Peng Y, Li PP, Li L, Zhang Y, Hou WZ, Cui DD, Li J, Wang L, Wang QL, Wang XL.

Yao Xue Xue Bao. 2016 Aug;51(8):1185-95.

Into the Light: Reflections on Whole-Systems Research After a Case Series Finds Reversal of Alzheimer's

Weeks J.

J Altern Complement Med. 2016 Aug;22(8):585-7. doi: 10.1089/acm.2016.29008.jjw.

Older patients are still under-represented in clinical trials of Alzheimer's disease

Banzi R, Camaioni P, Tettamanti M, Bertele' V, Lucca U.

Alzheimers Res Ther. 2016 Aug 12;8:32. doi: 10.1186/s13195-016-0201-2.

Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation

Aaseth J, Alexander J, Bjørklund G, Hestad K, Dusek P, Roos PM, Alehagen U.

Biometals. 2016 Oct;29(5):827-39. doi: 10.1007/s10534-016-9959-8. Epub 2016 Aug 16.

Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease)

Piccionello AP, Cappello F.

Curr Pharm Des. 2016;22(26):3935-6. doi: 10.2174/138161282226160801224800.

Editorial: Combining Forces to Improve Alzheimer's Disease Drug Discovery: The Symptomatic Battle

Deguil J, Auffret A, Schenker E, Aujard F, Lamberty Y, Bartrès-Faz D, Blin O, Micallef J, Richardson JC, Bordet R.

CNS Neurol Disord Drug Targets. 2016;15(7):754-5. doi: 10.2174/187152731507160808200737.

Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances

Cazarim Mde S, Moriguti JC, Ogunjimi AT, Pereira LR.

Sao Paulo Med J. 2016 Jul-Aug;134(4):342-54. doi: 10.1590/1516-3180.2015.01980112.

Neuroprotective properties of mitochondria-targeted antioxidants of the SkQ-type

Isaev NK, Stelmashook EV, Genrikhs EE, Korshunova GA, Sumbatyan NV, Kapkaeva MR, Skulachev VP.

Rev Neurosci. 2016 Dec 1;27(8):849-855. doi: 10.1515/revneuro-2016-0036.

Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems

Bagli E, Goussia A, Moschos MM, Agnantis N, Kitsos G.

In Vivo. 2016 09-10;30(5):535-47.

A proposed preventive role for Gamma-hydroxybutyrate (Xyrem(R)) in Alzheimer's disease

Maitre M, Klein C, Mensah-Nyagan AG.

Alzheimers Res Ther. 2016 Sep 6;8(1):37. doi: 10.1186/s13195-016-0205-y.

Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease

Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM.

Adv Nutr. 2016 Sep 15;7(5):905-16. doi: 10.3945/an.116.012187. Print 2016 Sep.

Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics

Athanasopoulos D, Karagiannis G, Tsolaki M.

Adv Nutr. 2016 Sep 15;7(5):917-27. doi: 10.3945/an.116.012229. Print 2016 Sep.

Drug development in Alzheimer's disease: the path to 2025

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P.

Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias